论文部分内容阅读
目的观察普拉克索联合持续正压通气(CPAP)对阻塞性睡眠呼吸暂停低通气综合征(OSAHS)合并不宁腿综合征(RLS)患者睡眠障碍的影响。方法将40例OSAHS合并RLS患者随机分为对照组和观察组,每组20例。对照组在CPAP治疗基础上加用安慰剂,每晚1次;观察组在CPAP治疗基础上加用普拉克索0.125 mg,每晚1次。疗程6 mo。比较2组治疗前后睡眠呼吸紊乱指数(AHI)、周期性腿动指数(PLMI)、腿动指数(LMI)、国际不宁腿量表(IRLS)评分和Epworth嗜睡量表(ESS)评分。结果 2组治疗后各指标均较治疗前有显著下降(P<0.05,P<0.01),治疗后AHI、PLMI、LMI在组间有非常显著差异(均P<0.01)。对照组和观察组IRLS评分(12.00±3.13 vs.7.00±2.13)和ESS评分(3.51±1.28 vs.6.39±1.35)组间比较均有非常显著差异(P<0.01)。结论普拉克索联合CPAP治疗OSAHS合并RLS患者睡眠障碍安全、有效。
Objective To investigate the effect of pramipexole combined with continuous positive airway pressure (CPAP) on sleep disorders in patients with obstructive sleep apnea-hypopnea syndrome (OSAHS) and restless legs syndrome (RLS). Methods Forty OSAHS patients with RLS were randomly divided into control group and observation group, with 20 cases in each group. The control group was treated with CPAP plus placebo once a night. The observation group was given pramipexole 0.125 mg once a night on the basis of CPAP treatment. Treatment 6 mo. The AHI, PLMI, LMI, IRLS and ESS scores of the two groups were compared before and after treatment. Results After treatment, the indexes of both groups were significantly decreased (P <0.05, P <0.01). There were significant differences in AHI, PLMI and LMI between the two groups after treatment (all P <0.01). The IRLS score (12.00 ± 3.13 vs.7.00 ± 2.13) and ESS score (3.51 ± 1.28 vs.6.39 ± 1.35) in the control group and the observation group were significantly different (P <0.01). Conclusions Pramipexole plus CPAP is safe and effective in treating sleep disorders in OSAHS patients with RLS.